Our research focuses on developing innovative therapies for mental health conditions, particularly treatment-resistant depression, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). We conduct clinical trials and investigative studies exploring and developing various treatment approaches, including device-based therapies like Transcranial Magnetic Stimulation (TMS) and transcranial Alternating Current Stimulation (tACS), as well as novel pharmacotherapies such as psychedelic-assisted therapy (psilocybin, MDMA). We also conduct neuroscience research (Electroencephalography [EEG]; Magnetic Resonance Imaging [MRI]) to better understand brain function in mental health conditions, aiming to inform and enhance treatment applications.

Together, our approach combines cutting-edge clinical trials with fundamental research, embedded within a strong translational focus. To do so, we hold established partnerships with clinical services throughout Australia, facilitating the implementation of our research findings in real-world settings. We have also developed training programs to educate healthcare professionals on these new treatment approaches, ensuring that the latest advancements in mental health care can be effectively and safely applied. This approach ensures that our research can rapidly transition from research trials to clinical implementation, potentially benefiting more people who have not responded to traditional treatments, and sooner.